Leonard G. Gomella, MD, FACS, presented “Update: Studies Combining Secondary Biomarkers and MRI” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Gomella, Leonard G. “Update: Studies Combining Secondary Biomarkers and MRI.” February 9, 2025. Accessed Nov 2025. https://grandroundsinurology.com/studies-combining-secondary-biomarkers-and-mri/
Update: Studies Combining Secondary Biomarkers and MRI – Summary
Leonard G. Gomella, MD, FACS, Thomas Jefferson University, Philadelphia, Pennsylvania, presents a comprehensive overview of combining secondary biomarkers with MRI. In this 15-minute presentation, Dr. Gomella emphasizes the need to reduce diagnoses of clinically insignificant prostate cancer while improving the identification of clinically significant cases.
Dr. Gomella identifies multiparametric MRI as a powerful tool in prostate cancer detection but highlights its limitations, particularly the risk of missing high-grade cancers. He underscores the potential for biomarkers to complement mpMRI by improving detection in cases with negative imaging. Citing studies such as PROMIS and PRECISION, he demonstrates that MRI alone may fail to identify certain significant cancers, creating opportunities for biomarker integration.
Dr. Gomella introduces key biomarkers like Select MDx and the 4Kscore, which have shown promise in enhancing diagnostic accuracy when combined with MRI. The ongoing ReIMAGINE trial aims to further explore the utility of combining these approaches in identifying significant prostate cancer cases.
Dr. Gomella highlights the economic implications, suggesting that biomarkers may offer a cost-effective alternative in specific clinical settings. He concludes that while multiparametric MRI remains a vital diagnostic tool, integrating biomarkers may significantly improve outcomes. He encourages further investigation into refining diagnostic pathways to enhance early detection strategies.
About the 35th International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.
ABOUT THE AUTHOR
Leonard G. Gomella, MD, FACS, completed medical school and general surgery and urology training at the University of Kentucky in Lexington. After a urologic oncology fellowship in the surgery branch of the National Cancer Institute, National Institutes of Health in Bethesda, Maryland. Dr. Gomella is currently the Bernard W. Godwin, Jr. Professor of Prostate Cancer, Chairman of the Department of Urology, Senior Director of Clinical Affairs for the Sidney Kimmel Comprehensive Cancer Center, and the Enterprise VP of Urology at the Jefferson Health System, at Thomas Jefferson University in Philadelphia, Pennsylvania.
